Judith Bushong

1.1k total citations
11 papers, 94 citations indexed

About

Judith Bushong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Judith Bushong has authored 11 papers receiving a total of 94 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Judith Bushong's work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Judith Bushong is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Judith Bushong collaborates with scholars based in United States, Japan and Spain. Judith Bushong's co-authors include Martin Reck, Hossein Borghaei, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Luis Paz‐Ares, Julie R. Brahmer, Kenneth J. O’Byrne, Phuong Tran, Makoto Nishio and Randeep Sangha and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Judith Bushong

10 papers receiving 92 citations

Peers

Countries citing papers authored by Judith Bushong

Since Specialization

Citations

This map shows the geographic impact of Judith Bushong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Bushong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Bushong more than expected).

Fields of papers citing papers by Judith Bushong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Bushong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Bushong. The network helps show where Judith Bushong may publish in the future.

Co-authorship network of co-authors of Judith Bushong

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Bushong. A scholar is included among the top collaborators of Judith Bushong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Bushong. Judith Bushong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1 2025 ·Journal of Thoracic Oncology ·Solange Peters, Meredith M. Regan, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne, Julie R. Brahmer, John R. Penrod, Jianqing Li, LaRee Tracy, Yong Yuan, Judith Bushong, Adam Lee, Laura J. Eccles, (unknown), Suresh S. Ramalingam	0
2	Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816 2023 ·Cancer Research ·Changli Wang, Ke‐Neng Chen, Qixun Chen, Lin Wu, Qun Wang, Xiaofei Li, (unknown), Wenxiang Wang, Jian Zhao, Lunxu Liu, Junke Fu, Chunfang Zhang, Jichun Liu, (unknown), Mark M. Awad, (unknown), Junliang Cai, Judith Bushong, Phuong Tran, Shun Lu	1
3	84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816 2023 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Judith Bushong, (unknown), (unknown), (unknown)	28
4	Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816 2023 ·ESMO Open ·Cheng Wang, (unknown), Qing Chen, Liangliang Wu, Qun Wang, Xiaoling Li, Kejing Ying, Weili Wang, Jie Zhao, Libo Liu, Jia Fu, Cheng Zhang, Jia Liu, (unknown), (unknown), Jinhua Cai, Judith Bushong, (unknown), Shun Lü	7
5	First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1 2023 ·International Journal of Clinical Oncology ·Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, Toshihide Yokoyama, Hidetoshi Hayashi, Tatsuro Fukuhara, Yuki Sato, Hiroshi Tanaka, Katsuyuki Hotta, Shunichi Sugawara, Haruko Daga, Isamu Okamoto, Kazuo Kasahara, Tateaki Naito, Li Li, (unknown), Judith Bushong, Hideaki Mizutani	4
6	LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743 2022 ·Annals of Oncology ·Gérard Zalcman, (unknown), Robin Cornelissen, Laurent Greillier, (unknown), Julien Mazières, Peter Briggs, Anna K. Nowak, Anne S. Tsao, (unknown), Solange Peters, Aaron S. Mansfield, Sanjay Popat, (unknown), Judith Bushong, Nan Hu, Thomas Spires, David Balli, Laura J. Eccles, Paul Baas	5
7	10P Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO+IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227 2022 ·Annals of Oncology ·Solange Peters, J.R. Penrod, Jianqing Li, Solomon J. Lubinga, Ruchira Das Gupta, Judith Bushong, Jasmine I. Rizzo, Suresh S. Ramalingam	2
8	Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227. 2022 ·Journal of Clinical Oncology ·Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu, (unknown), Makoto Nishio, (unknown), Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne, (unknown), Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam	10
9	Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816. 2022 ·Journal of Clinical Oncology ·(unknown), Jonathan Spicer, Janis M. Taube, Claudio Martín, David R. Spigel, Changli Wang, Nicolas Girard, Shun Lü, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Julie R. Brahmer, Stephen Broderick, Steven Swanson, Keith M. Kerr, Li Li, Junliang Cai, Judith Bushong, Phuong Tran, Patrick M. Forde	15
10	122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 2021 ·Annals of Oncology ·Martin Reck, Tudor–Eliade Ciuleanu, Adam Płużański, (unknown), Reyes Bernabé, Helena Linardou, (unknown), Carlos Gallardo, Makoto Nishio, Solange Peters, Luis Paz‐Ares, Matthew D. Hellmann, Hossein Borghaei, Suresh S. Ramalingam, Kenneth J. O’Byrne, Nan Hu, Judith Bushong, Laura J. Eccles, Diederik J. Grootendorst, Julie R. Brahmer	5
11	Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. 2021 ·Journal of Clinical Oncology ·Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabé, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Adam Płużański, Suresh S. Ramalingam, Julie R. Brahmer, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Judith Bushong, Phuong Tran, Martin Reck	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact